Matrox display controllers support new Eizo displays, TaraMed expands partnership

TriMed Staff | | Health Imaging | Diagnostic Imaging
Eizo Nanao Technologies Inc. this week announced that its recently released RadiForce G22 and R12 medical displays are compatible with Matrox Graphics Inc.'s MED2mp and RAD2mp display controller boards.

Matrox's RAD2mp display controllers, which support up to 2 mega-pixel (MP) grayscale or color, analog or digital displays, are designed for review and diagnostic stations, offers image manipulation, and support from the Matrox Imaging Library (MIL) software development toolkit.

The Matrox MED Series of display controllers provides multi-monitor support, high image quality and robust drivers. According to Matrox, the controllers are compatible with all display types with support for OpenGL in grayscale.

In related news, TaraMed, the Totoku authorized distributor of medical products for Ireland and the UK, and that currently supplies Matrox MED3mp and MED5mp display controller boards, has added Matrox's MED and RAD Series display controllers, ranging from 2 MP to 5 MP, with its medical displays.

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

Cardiovascular Business
FDA clears AI tool that flags signs of heart disease in chest CT scans

The newly cleared offering, AutoChamber, was designed with opportunistic screening in mind. It can evaluate many different kinds of CT images, including those originally gathered to screen patients for lung cancer. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup